Integral Diagnostics

The Business

IDX operates 142 clinics across Australia and New Zealand, staffed by 468 radiologists, generating $789 million of revenue in FY26. The core Australian business, roughly 94% of group revenue, provides X-ray, CT, MRI and ultrasound services billed predominantly through Medicare, with growth coming from an ageing population, government screening programs, and a gradual shift toward higher-value modalities. A teleradiology arm, IDXt, now reports 143 radiologists and is growing volumes more than 30% a year, distributing reporting workload nationally to counter a structural radiologist shortage. New Zealand, roughly 6% of revenue, is loss-making and under strategic review.

Recent Performance

Revenue jumped 26% in FY26 to $789 million, largely reflecting the December 2024 Capitol Health acquisition rather than organic momentum, while EBITDA margin held at 20.9% as cost synergies of $14 million beat the original $10 million target. The stock trades at $2.39, near multi-year lows, after a simultaneous CEO and CFO departure unsettled the market despite the operational result coming in ahead of plan.

Outlook

Revenue growth is expected to moderate from the acquisition-driven surge of FY26 to a mid-single-digit organic pace over the next three years, supported by Medicare volume growth, indexation, and a step-up from MRI deregulation in mid-2027. EBITDA margin is expected to hold broadly near current levels, as radiologist wage inflation of 4-5% partly offsets productivity gains from teleradiology. Earnings per share are forecast to grow at a high-single-digit to low-double-digit annual rate over the next three years, though the pace depends heavily on how smoothly the leadership transition unfolds.

Key Risks

The dual CEO and CFO transition is the single biggest swing factor for the thesis. A new chief executive with under 90 days in the role, paired with a vacant CFO seat, leaves the finance function without a permanent senior leader at a delicate point in the Capitol integration, and a stalled integration would materially compress earnings. Radiologist wage inflation running at 4-5% against Medicare indexation of just 2.4% is a separate, structural pressure on margins that the teleradiology platform can only partly offset. Goodwill equal to 117% of shareholder equity leaves thin headroom against a New Zealand impairment, a risk that would hit reported earnings without directly affecting cash flow.

What to Watch

The thesis-defining event is the FY27 first-half result in February 2027, which will show whether the new chief executive can hold Capitol's organic growth at an acceptable pace without a permanent chief financial officer in place. A CFO appointment, expected by October 2026, would remove a governance overhang that is currently weighing on sentiment. MRI deregulation in July 2027 is a separate, timing-certain catalyst independent of management execution.

• Oct 2026 Permanent CFO appointment — removes a key governance overhang; roughly 50% probability on this timeline.
• Feb 2027 FY27 H1 results — first real test of new CEO execution on Capitol integration.
• Jul 2027 MRI deregulation effective — 21 previously unlicensed machines become Medicare-billable, adding an estimated $10-15 million of high-margin revenue.

Latest Developments

IDX's chief executive and chief financial officer both departed within the past year, with a new chief executive now in place for under 90 days and using notably generic language in his appointment statement. The chief financial officer role remains vacant, a gap the market appears to be treating as a serious governance risk rather than a temporary staffing issue.

Company Description

Integral Diagnostics is Australia and New Zealand's second-largest diagnostic imaging provider, operating 142 clinics with 468 radiologists across X-ray, CT, MRI, ultrasound and nuclear medicine. The Australian business, roughly 94% of group revenue, bills predominantly through Medicare and has been reshaped by the December 2024 acquisition of Capitol Health, which added scale in Victoria and New South Wales. New Zealand contributes the remaining 6% of revenue and is currently loss-making, prompting a strategic review of its future within the group. A teleradiology division, IDXt, now employs 143 radiologists reporting remotely across the network, addressing capacity constraints in regional and outer-metropolitan areas where local radiologist supply cannot keep pace with imaging demand.

Where the Growth Is

The clearest near-term growth driver is MRI deregulation, effective July 2027, which will make 21 currently unlicensed MRI machines eligible for Medicare billing. Because the equipment is already installed and depreciated, the incremental revenue, estimated at $10-15 million in FY28-29, carries an incremental margin above 80%. This is a confirmed regulatory change rather than a forecast assumption, removing much of the execution risk attached to other growth levers. It is, however, modest relative to the group's overall revenue base, adding roughly 1-2 percentage points to growth in the years it lands rather than reshaping the medium-term trajectory.

Competitive Position

IDX's advantage rests on scale rather than pricing power, since Medicare sets the schedule fee for the vast majority of services performed. As the number two operator nationally, its network of 142 clinics gives it procurement leverage over equipment and consumables, and geographic density that smaller independent operators cannot easily replicate. The IDXt teleradiology platform reinforces this by pooling radiologist capacity across the network, a response to an industry-wide shortage that has pushed annual wage growth to 4-5%, well above the 2.4% Medicare indexation rate. This advantage is real but not wide: the primary competitor, I-MED, is private-equity owned with roughly 250 clinics and stated ambitions to expand aggressively into IDX's core markets, and radiologist mobility limits how sticky any scale advantage can be. We see this competitive position holding for 5-7 years before requiring meaningful reinvestment or facing a serious competitive response.

Management & Capital Discipline

Capital allocation to date has centred on M&A: the Capitol Health acquisition delivered $14 million of synergies against a $10 million target and lifted free cash flow conversion to 82%, both genuine wins for the prior management team. Set against that, Capitol remains dilutive to returns on capital, generating 7.6% against an 8.5% cost of capital, meaning the deal has not yet earned back its cost. The honest observation is that the current chief executive has been in the role for under 90 days, has no prior track record at IDX, and used notably generic language in his appointment statement. The chief financial officer seat remains vacant, leaving the finance function without a permanent leader at a delicate point in the integration.

Financial Position

Net debt sits above two times EBITDA, a level management is targeting to bring below 2.0x as free cash flow builds, while goodwill from past acquisitions equals 117% of shareholder equity, leaving thin headroom against a write-down should the New Zealand business deteriorate further. Free cash flow conversion of 82% in FY26 and a payout ratio of around 70% suggest the balance sheet can fund the dividend and ongoing capital expenditure of roughly $50 million a year without further borrowing. The business should weather a moderate downturn comfortably, given the non-discretionary nature of its Medicare-funded revenue, but has limited capacity to absorb a large one-off impairment.